Lineage Cell Therapeutics (LCTX) News Today $0.56 +0.06 (+11.16%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Lineage Cell Therapeutics, Inc. (LCTX.TA)December 10, 2024 | finance.yahoo.comLineage Cell Therapeutics FY2024 EPS Lifted by HC WainwrightLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Analysts at HC Wainwright upped their FY2024 EPS estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Wednesday, December 4th. HC Wainwright analyst J. Pantginis now anticipates that the comDecember 6, 2024 | marketbeat.comIs Lineage Cell Therapeutics (LCTX) the Best New Pick in Brad Gerstner’s Portfolio?December 1, 2024 | insidermonkey.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Purchases $24,000.00 in StockNovember 23, 2024 | insidertrades.comBrian M. Culley Acquires 40,000 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) StockLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) CEO Brian M. Culley purchased 40,000 shares of the firm's stock in a transaction on Thursday, November 21st. The stock was bought at an average cost of $0.60 per share, for a total transaction of $24,000.00. Following the completion of the purchase, the chief executive officer now directly owns 194,842 shares in the company, valued at approximately $116,905.20. This trade represents a 25.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.November 22, 2024 | marketbeat.comLineage Therap Announces $66 Million Direct OfferingNovember 21, 2024 | markets.businessinsider.comLineage Cell Therapeutics FY2024 EPS Raised by Cantor FitzgeraldLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Analysts at Cantor Fitzgerald upped their FY2024 EPS estimates for Lineage Cell Therapeutics in a report issued on Monday, November 18th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per sNovember 21, 2024 | marketbeat.comLineage Cell price target lowered to $2 from $3 at D. Boral CapitalNovember 20, 2024 | markets.businessinsider.comLineage Cell Therapeutics tumbles after pricing $66M securities offeringNovember 20, 2024 | msn.comLineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct OfferingNovember 20, 2024 | finance.yahoo.comD. Boral Capital Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy RecommendationNovember 19, 2024 | msn.comLineage Cell Therapeutics initiated with a Buy at D. Boral CapitalNovember 18, 2024 | markets.businessinsider.comLineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...November 15, 2024 | uk.finance.yahoo.comLineage Cell Therapeutics Reports Q3 2024 HighlightsNovember 15, 2024 | markets.businessinsider.comLineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comLineage Cell Therapeutics's Earnings OutlookNovember 13, 2024 | benzinga.comLineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare SummitOctober 14, 2024 | businesswire.comLogos Global Management LP Decreases Stock Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)Logos Global Management LP cut its stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 24.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,700,000 shares of theOctober 1, 2024 | marketbeat.comOpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International SymposiumSeptember 25, 2024 | businesswire.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) is Raffles Associates LP's 8th Largest PositionRaffles Associates LP increased its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 35.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,357,78September 24, 2024 | marketbeat.comLineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology WorkshopSeptember 18, 2024 | finance.yahoo.comMBX Biosciences Inc.September 17, 2024 | money.usnews.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Short Interest Up 6.5% in AugustLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 15,510,000 shares, an increase of 6.5% from the July 31st total of 14,560,000 shares. Based on an average daily trading volume, of 796,300 shares, the days-to-cover ratio is presently 19.5 days.September 2, 2024 | marketbeat.comCraig-Hallum Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy RecommendationAugust 21, 2024 | msn.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from Analysts at Craig HallumCraig Hallum started coverage on Lineage Cell Therapeutics in a report on Tuesday. They issued a "buy" rating and a $4.00 price target on the stock.August 20, 2024 | marketbeat.comBuy Rating Affirmed for Lineage Cell Therapeutics Amid Strategic Partnerships and Pipeline ProgressAugust 13, 2024 | markets.businessinsider.comLineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 13, 2024 | finance.yahoo.comLineage Cell Therapeutics: A Buy Rating Amidst Financial Stability and Promising Clinical ProgressAugust 10, 2024 | markets.businessinsider.comLineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Short Interest Up 12.7% in JulyLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totalling 14,560,000 shares, a growth of 12.7% from the June 30th total of 12,920,000 shares. Based on an average daily trading volume, of 950,200 shares, the days-to-cover ratio is presently 15.3 days.July 29, 2024 | marketbeat.comBuy Rating Affirmed for Lineage Cell Therapeutics on Promising OpRegen Trials and Strategic Roche PartnershipJuly 26, 2024 | markets.businessinsider.comLineage Cell Therapeutics, Inc. (LCTX)July 23, 2024 | finance.yahoo.comArtiva Biotherapeutics IncJuly 22, 2024 | money.usnews.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Down 1%Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Down 1%July 20, 2024 | marketbeat.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Down 1.5%Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Down 1.5%June 27, 2024 | marketbeat.comLineage to Present at 2024 BIO International ConventionMay 30, 2024 | businesswire.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Acquires $10,500.00 in StockMay 29, 2024 | insidertrades.comLineage Cell Therapeutics Inc.May 26, 2024 | barrons.comLineage Announces Updates to 2nd Annual Spinal Cord Injury Investor SymposiumMay 21, 2024 | finance.yahoo.comBuy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid FinancialsMay 14, 2024 | markets.businessinsider.comQ1 2024 Lineage Cell Therapeutics Inc Earnings CallMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue DeclinesMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | businesswire.comBrokers Set Expectations for Lineage Cell Therapeutics, Inc.'s FY2026 Earnings (NYSEAMERICAN:LCTX)Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a report issued on Monday, May 6th. HC Wainwright analyst J. Pantginis forecasts that the companyMay 9, 2024 | marketbeat.comBuy Rating for Lineage Cell Therapeutics as OpRegen Shows Durable Benefits for GA PatientsMay 8, 2024 | markets.businessinsider.comMaintained Buy Rating for Lineage Cell Therapeutics on Robust Clinical Trial Results and Strong Partnership with RocheMay 6, 2024 | markets.businessinsider.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday.May 6, 2024 | marketbeat.comOpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitMay 6, 2024 | businesswire.comLineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024May 2, 2024 | businesswire.com Get Lineage Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. LCTX Media Mentions By Week LCTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LCTX News Sentiment▼0.500.60▲Average Medical News Sentiment LCTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LCTX Articles This Week▼01▲LCTX Articles Average Week Get Lineage Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Zevra Therapeutics News Verve Therapeutics News Corvus Pharmaceuticals News SIGA Technologies News Arcturus Therapeutics News Kodiak Sciences News Y-mAbs Therapeutics News Aura Biosciences News Korro Bio News KalVista Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:LCTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LCTX Stock Alerts